Trial Profile

A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; VRC 01LS (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use
Acronyms ACTG A5357

16 May 2024 Status changed from active, no longer recruiting to completed.
06 Mar 2024 Results assessing safety and efficacy of VRC07-523LS Plus Long-Acting Cabotegravir, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
28 Feb 2024 According to a GSK media release, efficacy and safety data from this study will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) being held in Denver, Colorado, from 3-6 March 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com